Labcorp Announces Nationwide Availability Of ColoSense, Its RNA-Based, At-Home Colorectal Cancer Screening Test

Labcorp Holdings Inc.

Labcorp Holdings Inc.

LH

0.00
  • First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas
  • Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling
  • Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN)
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.